Vion Pharmaceuticals (United States)

Recent papers from Vion Pharmaceuticals (United States)

1. The Clinical and Economic Burden of Severe Leukocyte Adhesion Deficiency-I: A Lifetime Cost-of-Illness Modeling AnalysisJournal of Human Immunity · 2026
2. Safety, Pharmacokinetics, and Pharmacodynamics of Fixed-dose, Subcutaneous, and Intravenous Administration of VEL-101, an Anti-CD28 PEGylated Monoclonal Antibody Fragment, in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase 1 StudyTransplantation · 2026
3. Traits, Vision, and Professionalism of Social Workers in ChinaThe British Journal of Social Work · 2026
4. Bio-inspired alula-based winglet design for enhanced heat transfer in high temperature fin-and-tube heat exchangersInternational Journal of Heat and Mass Transfer · 2026
5. Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosisBlood · 2025
6. Verticillin A-Loaded Surgical Buttresses Prevent Local Pancreatic Cancer Recurrence in a Murine ModelMolecular Pharmaceutics · 2025
7. Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response ratesBlood Advances · 2024
8. A real-world data analysis of electronic health records to investigate the associations of predominant negative symptoms with healthcare resource utilisation, costs and treatment patterns among patients with schizophreniaBMJ Open · 2024
9. Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settingsAmerican Heart Journal · 2024
10. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson’s Disease: An Open-Label, Randomized, Crossover StudyJournal of Parkinson s Disease · 2023
11. Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)Circulation Arrhythmia and Electrophysiology · 2023
12. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy SubjectsClinical Pharmacokinetics · 2023
13. Alterations in Adipose Tissue Distribution, Cell Morphology, and Function Mark Primary Insulin Hypersecretion in Youth With ObesityDiabetes · 2023
14. A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug LabelsAdvances in Therapy · 2023
15. Long-term quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetateEpilepsy & Behavior · 2023
16. A protein kinase C α and β inhibitor blunts hyperphagia to halt renal function decline and reduces adiposity in a rat model of obesity-driven type 2 diabetesScientific Reports · 2023
17. Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypySchizophrenia · 2023
18. The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic FrameworkThe Journal of Clinical Psychiatry · 2023
19. The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar DepressionThe Journal of Clinical Psychiatry · 2023
20. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophreniaEuropean Archives of Psychiatry and Clinical Neuroscience · 2023